{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041840","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.351269+00:00","generated_at":"2026-06-11T15:02:44.929511+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revelation Biosciences receives Nasdaq bid price deficiency notice","bullets":["Nasdaq notified REVB on Aug 8, 2023 of noncompliance with minimum $1.00 bid price rule for 30 consecutive business days.","Company has a 180-day grace period until Feb 5, 2024 to regain compliance; common stock must close at $1.00+ for 10 consecutive days.","If not cured, may be eligible for an additional 180-day extension pending meeting other listing standards and reverse stock split if needed.","Noncompliance has no immediate impact on trading; stock continues listed on Nasdaq Capital Market.","Company is evaluating options to maintain listing including potential reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041840","json":"https://secwatch.observer/filing/0000950170-23-041840.json","markdown":"https://secwatch.observer/filing/0000950170-23-041840.md","text":"https://secwatch.observer/filing/0000950170-23-041840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041840/0000950170-23-041840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041840/revb-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:02:44.929511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf313a250cbe1f1bc221f21352d0ee20dab0d99c","claim":"REVELATION BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 8, 2023, Revelation Biosciences, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by failing to maintain a minimum bid price for its common stock of at least $1.00 per share for 30 consecutive business days. According to the letter, the Company has a 180 calendar day grace period to regain compliance with the Rule (the “Grace Period”), subject to a potential 180 calendar day extension, as described below. To regain compliance, the Company’s common stock must have","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023041840/0000950170-23-041840-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}